Last reviewed · How we verify
NCT06202625: Haplo-HSCT
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
Phase 2, PHASE3 trial testing avatrombopag in Thrombocytopenia in 142 participants. Currently enrolling.
30 October 2024
Quick facts
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 142 |
| Start date | 13 May 2024 |
| Primary completion | 30 October 2024 |
| Estimated completion | 30 October 2025 |
| Sites | 14 locations across China |
Drugs / interventions tested
- avatrombopag (AVATROMBOPAG) — full drug profile →
- Placebo
Conditions studied
- Thrombocytopenia — all drugs for Thrombocytopenia →
- Stem Cell Transplant Complications — all drugs for Stem Cell Transplant Complications →
Sponsor
Peking University People's Hospital
Who can join
Adults 18 to 65, any sex, with Thrombocytopenia or Stem Cell Transplant Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, investigators aim to evaluate the efficacy of avatrombopag in thrombocytopenic patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) through a prospective, multi-center, double-blinded, randomized placebo-controlled clinical trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06202625
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of avatrombopag
Trials testing the same drug.
- NCT05720234 — Avatrombopag Combined With IST as First-line Treatment for SAA · Phase 2 · unknown
- NCT05518331 — The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA · NA · unknown
Other recruiting trials for Thrombocytopenia
Currently open trials in the same condition.
- NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
- NCT07442513 — Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT · Phase 3 · recruiting
- NCT07257809 — Herombopag Treated T-DM1 Induced Platelet Reduction · Phase 2 · recruiting
- NCT06676904 — Neonatal Platelet Transfusion Threshold Trial · NA · recruiting
- NCT06886516 — Apixaban in Thrombocytopenia · EARLY_PHASE1 · recruiting
Other Peking University People's Hospital trials
Trials by the same sponsor.
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
- NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
- NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06202625 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
- Last refreshed: 1 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06202625.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing